Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.78 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.78 |
| ▸ | NQO2 | P16083 | 4/20 | 0.78 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30852855 | 1.00 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL5144427 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL27714153 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL3224617 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL1309580 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL8717163 | 0.85 | MTNR1A (0.74) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL25100780 | 0.84 | MTNR1A (0.77) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL194360 | 0.84 | MTNR1A (0.73) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL23950140 | 0.83 | MTNR1A (0.71) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL31543623 | 0.83 | MTNR1A (0.56) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053462-B2 | Indole derivative and application thereof | SOMEI MASANORI | 2011-11-08 | — | — | US | disclosed |
| US-8053462-B2 | Indole derivative and application thereof | SOMEI MASANORI | 2011-11-08 | — | — | US | disclosed |
| US-8053462-B2 | Indole derivative and application thereof | SOMEI MASANORI | 2011-11-08 | — | — | US | disclosed |
| US-7872040-B2 | Receptor blocker and vasodilator comprising indole derivative as active ingredient | SOMEI MASANORI | 2011-01-18 | — | — | US | disclosed |
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20070197629-A1 | Indole derivative and application thereof | SOMEI MASANORI | 2007-08-23 | — | — | US | disclosed |
| US-20070197629-A1 | Indole derivative and application thereof | SOMEI MASANORI | 2007-08-23 | — | — | US | disclosed |
| US-20070197629-A1 | Indole derivative and application thereof | SOMEI MASANORI | 2007-08-23 | — | — | US | disclosed |
| US-20070129312-A1 | Convalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites | YATVIN MILTON B | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | ADRB2, ADRB1, ADRA2B | MTNR1A 261/4885MTNR1B 180/4885NQO2 1905/4885 |
| US-20070129312-A1 | Convalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites | SLC7A1, SLC1A1, DNPEP | MTNR1A 1204/4885MTNR1B 2214/4885NQO2 382/4885 |
| US-20070197629-A1 | Indole derivative and application thereof | ARL1, IDO1, AIPL1 | MTNR1A 143/4885MTNR1B 287/4885NQO2 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.